PE20091157A1 - Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155 - Google Patents

Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155

Info

Publication number
PE20091157A1
PE20091157A1 PE2008002119A PE2008002119A PE20091157A1 PE 20091157 A1 PE20091157 A1 PE 20091157A1 PE 2008002119 A PE2008002119 A PE 2008002119A PE 2008002119 A PE2008002119 A PE 2008002119A PE 20091157 A1 PE20091157 A1 PE 20091157A1
Authority
PE
Peru
Prior art keywords
treatment
androgen receptor
triazolo
conditions associated
compounds
Prior art date
Application number
PE2008002119A
Other languages
English (en)
Inventor
Robert Hugh Bradbury
Alfred Arthur Rabow
Neil James Hales
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20091157A1 publication Critical patent/PE20091157A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS BICICLICOS DE FORMULA (Ic) DONDE X3 ES CH O N; R4 ES C2F2, CF3 O CClF2; Y ES CH, COH O N; R14 ES H O CH3; n Y p SON CADA UNO 1 O 2; L1 ES UN ENLACE DIRECTO, -S-, -S(O)-, -S(O)2-, ENTRE OTROS; J ES ARILO, UN ANILLO CARBOCICLICO DE 3 A 6 MIEMBROS MONOCICLICO, HETEROCICLICO DE 4 A 7 MIEMBROS, ENTRE OTROS; L3 ES -C(O)-(CH2)q, -O-(CH2)q, (CH2)q, ENTRE OTROS, DONDE q ES DE 0 A 3; R12 ES OH, HALO, AMINO, CN, OXO, ENTRE OTROS; r ES DE 0 A 3. SON COMPUESTOS PREFERIDOS: 4-[[4-[3-(TRIFLUOROMETIL)-[1,2,4]TRIAZOLO[4,3-b]PIRIDAZIN-6-IL]PIPERAZIN-1-IL]METIL]BENZONITRILO, 3-(TRIFLUOROMETIL)-6-[4-[[3-(TRIFLUOROMETIL)FENIL]METIL]PIPERAZIN-1-IL]-[1,2,4]TRIAZOLO[4,3-b]PIRIDAZINA, 4-PIRIDIN-3-IL-1-[3-(TRIFLUOROMETIL)-[1,2,4]TRIAZOLO[4,3-b]PIRIDAZIN-6-IL]PIPERIDIN-4-OL, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON LIGANDOS DEL RECEPTOR DE ANDROGENO (AR) SIENDO UTILES EN EL TRATAMIENTO DEL CANCER DE PROSTATA
PE2008002119A 2007-12-21 2008-12-18 Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155 PE20091157A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1575507P 2007-12-21 2007-12-21
US9609008P 2008-09-11 2008-09-11
US10780408P 2008-10-23 2008-10-23

Publications (1)

Publication Number Publication Date
PE20091157A1 true PE20091157A1 (es) 2009-09-03

Family

ID=40428336

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008002119A PE20091157A1 (es) 2007-12-21 2008-12-18 Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155

Country Status (23)

Country Link
US (1) US8003649B2 (es)
EP (1) EP2235010A1 (es)
JP (1) JP2011507824A (es)
KR (1) KR20100099742A (es)
CN (1) CN101952286A (es)
AR (1) AR069911A1 (es)
AU (1) AU2008339572B2 (es)
BR (1) BRPI0821676A2 (es)
CA (1) CA2709514A1 (es)
CL (1) CL2008003846A1 (es)
CO (1) CO6331441A2 (es)
CR (1) CR11524A (es)
DO (1) DOP2010000195A (es)
EA (1) EA017144B1 (es)
EC (1) ECSP10010291A (es)
IL (1) IL206284A0 (es)
NI (1) NI201000110A (es)
NZ (1) NZ586913A (es)
PE (1) PE20091157A1 (es)
TW (1) TW200927121A (es)
UY (1) UY31559A1 (es)
WO (1) WO2009081197A1 (es)
ZA (1) ZA201004227B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550505B2 (en) * 2006-07-24 2009-06-23 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
US8188083B2 (en) * 2007-06-28 2012-05-29 Abbott Laboratories Triazolopyridazines
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
US8067448B2 (en) 2008-02-22 2011-11-29 Radius Health, Inc. Selective androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
MY160526A (en) 2008-12-22 2017-03-15 Merck Patent Gmbh Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl}-2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
PE20120603A1 (es) * 2009-02-10 2012-06-14 Astrazeneca Ab Derivados de triazolo[4,3-b]piridazina y sus usos para el cancer de prostata
SG175726A1 (en) * 2009-05-11 2011-12-29 Astrazeneca Ab [1,2,4] triazolo [4,3-b] pyridazines as ligands of the androgen receptor
WO2011008543A2 (en) * 2009-06-29 2011-01-20 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
JP5847087B2 (ja) 2009-10-23 2016-01-20 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
EP2491038B1 (en) 2009-10-23 2016-04-06 Janssen Pharmaceutica N.V. Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators
JP5848251B2 (ja) 2009-10-23 2016-01-27 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
US8343977B2 (en) 2009-12-30 2013-01-01 Arqule, Inc. Substituted triazolo-pyrimidine compounds
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
WO2011143469A1 (en) 2010-05-12 2011-11-17 Radius Health,Inc Therapeutic regimens
JP5702855B2 (ja) * 2010-05-13 2015-04-15 アムジエン・インコーポレーテツド Ｐｄｅ１０阻害剤として有用な窒素複素環化合物
US9006450B2 (en) 2010-07-01 2015-04-14 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
ES2550319T3 (es) 2010-09-28 2015-11-06 Radius Health, Inc Moduladores selectivos del receptor de andrógenos
US9586962B2 (en) 2011-04-20 2017-03-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo [3,4-C] pyrroles as orexin receptor modulators
AR092982A1 (es) 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
US9422290B2 (en) * 2012-11-13 2016-08-23 Boehringer Ingelheim International Gmbh Triazolopyridazine
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
HUP1300139A2 (en) * 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
KR20160006215A (ko) 2013-05-13 2016-01-18 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 가교 우레아 유사체
US9428501B2 (en) * 2013-06-10 2016-08-30 Astellas Pharma Inc. Bicyclic nitrogen-containing aromatic heterocyclic amide compound
NO2719005T3 (es) 2014-07-28 2018-01-20
EP3034501A1 (en) * 2014-12-17 2016-06-22 Gilead Sciences, Inc. Hydroxy containing FXR (NR1H4) modulating compounds
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
WO2016161125A1 (en) * 2015-03-31 2016-10-06 University Of Vermont And State Agricultural College Methods for treating cryptosporidiosis using triazolopyridazines
CA2960253A1 (en) 2016-03-10 2017-09-10 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
PL3730487T3 (pl) 2016-06-13 2022-08-16 Gilead Sciences, Inc. Pochodne azetydyny jako modulatory fxr (nr1h4)
EP4066827A1 (en) 2016-06-22 2022-10-05 Ellipses Pharma Ltd Ar+ breast cancer treatment methods
JP6906626B2 (ja) 2017-03-28 2021-07-21 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置するための治療的組み合わせ
JP7266576B2 (ja) * 2017-08-04 2023-04-28 ブリストル－マイヤーズ スクイブ カンパニー ［１，２，４］トリアゾロ［４，３－ａ］ピリジニル置換のインドール化合物
GB201716871D0 (en) 2017-10-13 2017-11-29 Inst Of Cancer Research: Royal Cancer Hospital Compounds
GB201806663D0 (en) * 2018-04-24 2018-06-06 Avexxin As 2-Oxothiazole compositions for treatment of fibrotic disease
WO2020123670A1 (en) * 2018-12-11 2020-06-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of the androgen receptor activity and/or expression and uses thereof
CN109942574B (zh) * 2019-01-11 2022-04-01 成都阿奇生物医药科技有限公司 天奇替尼及其制备方法和用途
AU2020209564B2 (en) 2019-01-15 2022-12-01 Gilead Sciences, Inc. FXR (NR1H4) modulating compounds
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
EP4023649A1 (en) * 2020-12-30 2022-07-06 Industrial Technology Research Institute Androgen receptor binding bifunctional molecules

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1122242B1 (en) 1998-09-22 2008-01-16 Astellas Pharma Inc. Cyanophenyl derivatives
US6184249B1 (en) 1998-12-18 2001-02-06 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
US6472415B1 (en) 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
AU2005292134B2 (en) * 2004-10-01 2010-12-23 Merck Sharp & Dohme Corp. Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2008109104A1 (en) * 2007-03-07 2008-09-12 The Regents Of The University Of California Bivalent inhibitors of akt protein kinase

Also Published As

Publication number Publication date
DOP2010000195A (es) 2010-08-31
US20100016279A1 (en) 2010-01-21
NI201000110A (es) 2012-05-14
US8003649B2 (en) 2011-08-23
JP2011507824A (ja) 2011-03-10
TW200927121A (en) 2009-07-01
EP2235010A1 (en) 2010-10-06
CL2008003846A1 (es) 2010-02-05
AU2008339572A1 (en) 2009-07-02
ZA201004227B (en) 2011-10-26
EA017144B1 (ru) 2012-10-30
KR20100099742A (ko) 2010-09-13
IL206284A0 (en) 2010-12-30
BRPI0821676A2 (pt) 2015-06-16
CA2709514A1 (en) 2009-07-02
CO6331441A2 (es) 2011-10-20
UY31559A1 (es) 2009-08-03
ECSP10010291A (es) 2010-07-30
CN101952286A (zh) 2011-01-19
CR11524A (es) 2010-08-05
NZ586913A (en) 2012-06-29
WO2009081197A1 (en) 2009-07-02
AU2008339572B2 (en) 2012-05-10
EA201000946A1 (ru) 2010-12-30
AR069911A1 (es) 2010-03-03

Similar Documents

Publication Publication Date Title
PE20091157A1 (es) Derivados biciclicos para usar en el tratamiento de afecciones asociadas con el receptor de androgeno - 155
RU2019143759A (ru) Новое соединение бифенила или его соль
AR062886A1 (es) Compuestos de tiazol pirazolopirimidina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
PE20090884A1 (es) Compuestos de indol como activadores de glucoquinasa
PE20090477A1 (es) Derivados de oxazol como inhibidores de los canales de sodio
PE20081228A1 (es) Compuesto heteromonociclico
PE20100718A1 (es) Derivados triciclicos de 1, 4-dihidropiridina [b, e]-condensados como inhibidores de aurora quinasas
PE20090648A1 (es) Compuestos para el tratamiento de la hepatitis c
BRPI0506765A (pt) composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição
NZ600430A (en) Spiro-oxindole mdm2 antagonists
PE20110574A1 (es) Derivados de fenilamida y de piridilamida como agonistas de gpbar1
PE20061305A1 (es) Compuestos derivados de fenilacetamidas como inhibidores de proteincinasas
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
MX2010004819A (es) Derivados de [1h-pirazolo[3,4-b]piridin-4-il]-fenilo o piridin-2-ilo como proteina cinasa c-theta.
MX2007007103A (es) Derivados espiro como inhibidores de lipoxigenasa.
PE20070531A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
TW200635594A (en) Phenyl-piperazin methanone derivatives
AR064010A1 (es) Inhibidores de la actividad de la akt
PE20080925A1 (es) DERIVADOS DE PIRROLO[2,3-b]PIRIDINA COMO INHIBIDORES DE QUINASA, EN PARTICULAR INHIBIDORES IKK2 (O IKK BETA)
RU2008120850A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
PE20090674A1 (es) Compuestos multiciclicos
AR078542A1 (es) Moduladores de gpr40 de pirrolidina
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
PE20121137A1 (es) Antagonistas del receptor de cgrp
HK1110868A1 (en) Heterocyclic compounds as ccr2b antagonists

Legal Events

Date Code Title Description
FC Refusal